Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SKIN vs NWL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NWL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)
NWL Overall Winner
6-Pillar Tally: SKIN 3 – 3 NWL
Matrix Metrics: SKIN 1 – 9 NWL
As of Nov 16, 2026, Newell Brands Inc. (NWL) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas NWL carries 48.5/100 (HOLD) at $5.85 (8.4x Forward P/E, 7.8% operating margin).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SKIN vs NWL
SKIN
The Beauty Health Company Class A Common Stock
$15.05
-7.73% 1D
Market Cap
$106.3M
TTM Revenue
$289M
Forward P/E
106.4x
Beta / 30D Vol
-14.22β · 192% Vol
Unified Composite Score
34.1
SELL
Tech 50.0
Fund 34.0
Flow 67.0
Mom 46.0
Weinstein Technical Phase
Markup · Hold / add on dips
NWL
Head-to-Head Winner
Newell Brands Inc.
$5.85
+1.21% 1D
Market Cap
$2.5B
TTM Revenue
$7.31B
Forward P/E
8.4x
Beta / 30D Vol
1.28β · 76% Vol
Unified Composite Score
48.5
HOLD
Tech 40.0
Fund 49.0
Flow 57.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (SKIN 3 – 3 NWL)
1. Valuation Multiples
NWL
Forward P/E
106.4x
8.4x
Trailing P/E
106.4x
7.9x
PEG Ratio
0.93x
0.97x
EV / Revenue
0.9x
1.0x
2. Growth & Scale
NWL
Revenue Growth (YoY)
-2.1%
+3.7%
Earnings Growth (YoY)
+0.0%
+126.6%
TTM Revenue (USD)
$289M
$7.31B
Market Cap
$106.3M
$2.5B
3. Profitability & Quality
NWL
Gross Margin
67.2%
35.1%
Operating Margin
2.4%
7.8%
Net Profit Margin
-6.3%
-4.4%
Return on Equity (ROE)
-30.1%
-12.8%
4. Balance Sheet & Cash Flow
SKIN
Cash Generation (TTM)
$17M
$53M
Cash Flow Margin
5.8%
0.7%
Net Cash / Leverage
$161M Net Debt (6.61x D/E)
$5.12B Net Debt (2.27x D/E)
Dividend Yield
None (0.00%)
4.86%
5. Options & Positioning
SKIN
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
517.4% (100th %ile)
46.0% (48th %ile)
Put/Call OI Skew
N/A
0.05x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
SKIN
OpEx & R&D Intensity
64.8% of Rev ($187M)
27.3% of Rev ($2.00B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Household & Personal Products Operator
Household & Personal Products Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SKIN (1) vs NWL (9)| Institutional Metric | SKIN | NWL | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $106.3M | $2.5B | NWL | |
| Trailing P/E Ratio | 106.4x | 7.9x | NWL | |
| Forward P/E Ratio | 106.4x | 8.4x | NWL | |
| Revenue Growth (YoY) | -2.1% | +3.7% | NWL | |
| Operating Margin (TTM) | 2.4% | 7.8% | NWL | |
| Net Profit Margin | -6.3% | -4.4% | NWL | |
| Return on Equity (ROE) | -30.1% | -12.8% | NWL | |
| 52-Week Range Position | 83% ($0–$18) | 67% ($3–$7) | SKIN | |
| Beta / 30D Volatility | -14.22β · 192% Vol | 1.28β · 76% Vol | NWL | |
| Unified Institutional Score | 34.1 / 100 (SELL) | 48.5 / 100 (HOLD) | NWL | |
| Trailing 12M Revenue (USD) | $289M | $7.31B | Scale | |
| Gross Profit Margin (TTM) | 67.2% | 35.1% | Quality | |
| PEG Ratio & EV / Revenue | 0.93x PEG · 0.9x EV/Rev | 0.97x PEG · 1.0x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $17M ($161M Net Debt (6.61x D/E)) | $53M ($5.12B Net Debt (2.27x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SKIN +38.98 pp
3M Horizon
SKIN +2409.68 pp
6M Horizon
SKIN +2324.87 pp
1Y Horizon
SKIN +984.61 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SKIN Revenue | NWL Revenue | SKIN Op. Margin | NWL Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $10.2B | N/A | -74.4% | NWL |
| FY2019 | $170M | $9.71B | 8.1% | -5.0% | SKIN |
| FY2020 | $120M | $9.38B | -14.4% | -6.7% | NWL |
| FY2021 | $260M | $10.6B | -15.4% | 9.6% | NWL |
| FY2022 | $370M | $9.46B | -7.1% | 3.3% | NWL |
| FY2023 | $400M | $8.13B | -32.9% | -1.0% | NWL |
| FY2024 | $330M | $7.58B | -20.3% | 0.9% | NWL |
| FY2025 | $300M | $7.20B | -6.9% | 0.5% | NWL |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SKIN
UNCLASSIFIED
Current IV
517.4%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NWL
CONSOLIDATION
Current IV
46.0%
IV Percentile
48th %ile
Put/Call OI Skew
0.05x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NWL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SKIN Moat Profile
Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
OpEx & R&D Reinvestment
64.8% of Rev ($187M)
90D Engineering Disclosures
0 Published
NWL Moat Profile
Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
OpEx & R&D Reinvestment
27.3% of Rev ($2.00B)
90D Engineering Disclosures
0 Published
Investor FAQ SKIN vs NWL Key Questions & Quantitative Answers
As of Nov 16, 2026, Newell Brands Inc. (NWL) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas NWL carries 48.5/100 (HOLD) at $5.85 (8.4x Forward P/E, 7.8% operating margin). Technically, SKIN sits in a Markup phase (RSI 67.4, UNCLASSIFIED options structure) and NWL sits in a Neutral phase (RSI 54.7, CONSOLIDATION options structure).
NWL leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with NWL at +3.7% YoY revenue growth and +126.6% YoY earnings growth on $7.31B TTM revenue (35.1% gross margin, 7.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SKIN cumulative revenue shifted +76.5% while NWL shifted -29.1%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 27.3% of Rev ($2.00B) (0 disclosures) for NWL.
NWL screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas NWL trades at 8.4x Forward P/E, 7.9x Trailing P/E, 0.97x PEG, and 1.0x EV/Revenue (0.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus NWL (-12.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, NWL carries 46.0% implied volatility (48th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NWL vs SKIN · Reverse Pair
SKIN vs MRVI
· Sector Peer
SKIN vs FIGS
· Sector Peer
SKIN vs PRCH
· Sector Peer
NWL vs WHR
· Sector Peer
NWL vs CAG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem